新型信号通路和NSC689534作为皮肤状细胞癌的潜在候选药物

Ying Miao1, Cheng Shen2, Xin Zhang1

  • 1Department of Dermatology, Affiliated Hospital of Nantong University, Medical School of Nantong University, 226001 Nantong, Jiangsu, China.

概括

这项研究确定NSC689534作为治疗晚期皮肤状细胞癌 (cSCC) 的潜在药物. 它针对参与细胞分裂的关键基因TPX2和KIF11,为进展性cSCC患者提供希望.